Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance

Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance in patients with chronic myelogenous leukemia. Many mutations favor active kinase conformations that preclude imatinib binding. Because the active forms of ABL and SRC resemble one another, we tested two dual SRC-ABL...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Azam, Mohammad, Nardi, Valentina, Shakespeare, William C., Metcalf, Chester A., Bohacek, Regine S., Wang, Yihan, Sundaramoorthi, Raji, Sliz, Piotr, Veach, Darren R., Bornmann, William G., Clarkson, Bayard, Dalgarno, David C., Sawyer, Tomi K., Daley, George Q.
Format: Article
Langue:English
Publié: National Academy of Sciences 2006
Sujets:
Biological Sciences
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC1482597/
https://ncbi.nlm.nih.gov/pubmed/16754879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0600001103
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://ncbi.nlm.nih.gov/pmc/articles/PMC1482597/
https://ncbi.nlm.nih.gov/pubmed/16754879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0600001103

Documents similaires